Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.95 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.71 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.71 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 9/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL3362636 | 1.00 | SLC7A5 (0.95) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL20362356 | 0.97 | — | — | |
| D-Leucine SCHEMBL9100148 | 0.97 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL8568063 | 0.97 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL175940 | 0.97 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL25241602 | 0.97 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL2478164 | 0.97 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL8568060 | 0.97 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL9449950 | 0.97 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL331557 | 0.97 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118688352-A | Method for detecting dissolution rate of compound alpha-keto acid tablet | 重庆士立德医药科技有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118688350-A | Method for detecting ketoleucine and calcium impurities in compound alpha-keto acid tablet | 重庆士立德医药科技有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-110627638-B | Method for preparing ketoleucine calcium hydrate by one-step method and application thereof | 福安药业集团重庆博圣制药有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-108516931-B | Preparation method of alpha-ketoleucine calcium | 精晶药业股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-105640925-B | Dried powder formula and method for treating pulmonary disease | 普马特里克斯营业公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-103200938-B | Dry powder formulations and methods for treating pulmonary diseases | 普马特里克斯营业公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-103922949-A | Calcium leucine chelate powder and processing method thereof | UNIV JILIN | 2014-07-16 | — | — | CN | disclosed |
| CN-103922949-A | Calcium leucine chelate powder and processing method thereof | UNIV JILIN | 2014-07-16 | — | — | CN | disclosed |
| US-20100041622-A1 | Compositions containing aminoalkanes and aminoalkane derivatives | VIRUN, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010019255-A1 | COMPOSITIONS CONTAINING AMINOALKANES AND AMINOALKANE DERIVATIVES | VIRUN, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041622-A1 | Compositions containing aminoalkanes and aminoalkane derivatives | TAAR5, PDE3A, PDE2A | SLC7A5 564/4885SLC1A2 121/4885SLC1A3 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.